Medical devices, healthcare technology and the business of care
510(k) clearance · K253898

QT Scanner 2000 Model A

QT Imaging Holdings, Inc. · Decision date Mar 4, 2026

FDA DECISIONK253898

What did the FDA decide?

FDA records K253898 as a 510(k) premarket notification, with a decision dated Mar 4, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Radiology
Decision date
Mar 4, 2026

FDA source record

Regulatory record facts

Identifier
K253898
Regulatory pathway
510(k) premarket notification
Product code
IYO
Decision code
SESE
Decision date
Mar 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, Imaging, Pulsed Echo, Ultrasonic.

Product code
IYO
FDA device class
2

FDA decision timeline

  1. K253898 received

    Application receipt date recorded by FDA.

  2. K253898 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code IYO

Product / regulatory recordCompanyPathwayDecision dateSource
Evident Vascular, Inc.510(k) clearanceOct 28, 2026FDA
Accuro XVK262093
Rivanna Medical, Inc.510(k) clearanceOct 20, 2026FDA
Lilium Otsuka Co., Ltd.510(k) clearanceOct 16, 2026FDA
MEDA Co., Ltd.510(k) clearanceSep 24, 2026FDA
Accuro 3SK253452
Rivanna Medical, Inc.510(k) clearanceJul 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

QT Imaging Holdings, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Novato, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records